JP2019536757A5 - - Google Patents

Download PDF

Info

Publication number
JP2019536757A5
JP2019536757A5 JP2019520150A JP2019520150A JP2019536757A5 JP 2019536757 A5 JP2019536757 A5 JP 2019536757A5 JP 2019520150 A JP2019520150 A JP 2019520150A JP 2019520150 A JP2019520150 A JP 2019520150A JP 2019536757 A5 JP2019536757 A5 JP 2019536757A5
Authority
JP
Japan
Prior art keywords
muscle
trans
thiazole
carboxamide
yloxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019520150A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019536757A (ja
JP6938628B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2017/056320 external-priority patent/WO2018069863A1/en
Publication of JP2019536757A publication Critical patent/JP2019536757A/ja
Publication of JP2019536757A5 publication Critical patent/JP2019536757A5/ja
Application granted granted Critical
Publication of JP6938628B2 publication Critical patent/JP6938628B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019520150A 2016-10-13 2017-10-12 造血器型プロスタグランジンdシンターゼ阻害剤としての1,3二置換シクロブタンまたはアゼチジン誘導体 Expired - Fee Related JP6938628B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662407634P 2016-10-13 2016-10-13
US62/407,634 2016-10-13
PCT/IB2017/056320 WO2018069863A1 (en) 2016-10-13 2017-10-12 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin d synthase inhibitors

Publications (3)

Publication Number Publication Date
JP2019536757A JP2019536757A (ja) 2019-12-19
JP2019536757A5 true JP2019536757A5 (https=) 2020-12-24
JP6938628B2 JP6938628B2 (ja) 2021-09-22

Family

ID=60320926

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019520150A Expired - Fee Related JP6938628B2 (ja) 2016-10-13 2017-10-12 造血器型プロスタグランジンdシンターゼ阻害剤としての1,3二置換シクロブタンまたはアゼチジン誘導体

Country Status (24)

Country Link
US (1) US11053234B2 (https=)
EP (1) EP3526206A1 (https=)
JP (1) JP6938628B2 (https=)
KR (1) KR20190072565A (https=)
CN (1) CN110072857A (https=)
AR (1) AR109931A1 (https=)
AU (1) AU2017342156B2 (https=)
BR (1) BR112019007609A2 (https=)
CA (1) CA3038756A1 (https=)
CL (1) CL2019000986A1 (https=)
CO (1) CO2019003482A2 (https=)
CR (1) CR20190174A (https=)
DO (1) DOP2019000087A (https=)
EA (1) EA201990904A1 (https=)
IL (1) IL265597A (https=)
JO (1) JOP20190072A1 (https=)
MA (1) MA46531A (https=)
MX (1) MX2019004320A (https=)
PE (1) PE20191020A1 (https=)
PH (1) PH12019500811A1 (https=)
TW (1) TW201827412A (https=)
UY (1) UY37440A (https=)
WO (1) WO2018069863A1 (https=)
ZA (1) ZA201901848B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190072A1 (ar) 2016-10-13 2019-04-07 Glaxosmithkline Ip Dev Ltd مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم
TW201908311A (zh) * 2017-06-13 2019-03-01 英商葛蘭素史克智慧財產發展有限公司 化合物
CN118239937A (zh) * 2017-08-09 2024-06-25 戴纳立制药公司 化合物、组合物及方法
DK3676297T3 (da) 2017-09-01 2023-08-14 Denali Therapeutics Inc Forbindelser, sammensætninger og fremgangsmåder
US12091392B2 (en) 2019-02-13 2024-09-17 Denali Therapeutics Inc. Compounds, compositions and methods
MA54953A (fr) 2019-02-13 2021-12-22 Denali Therapeutics Inc Composés, compositions et procédés
WO2021152113A1 (en) 2020-01-31 2021-08-05 Bayer Aktiengesellschaft Substituted 2,3-benzodiazepines derivatives
WO2021207310A1 (en) 2020-04-08 2021-10-14 Agios Pharmaceuticals, Inc. Menin inhibitors and methods of use for treating cancer
CN113582880B (zh) * 2020-04-30 2023-11-17 南京药石科技股份有限公司 一种(3-氨基二环[1.1.1]戊烷-1-基)氨基甲酸叔丁酯的制备方法
CN111574473A (zh) * 2020-06-04 2020-08-25 宁夏农林科学院农业资源与环境研究所(宁夏土壤与植物营养重点实验室) 一种氨基噻唑类化合物的合成方法
CA3179059A1 (en) * 2020-06-09 2021-12-16 Anima Biotech Inc. Collagen 1 translation inhibitors and methods of use thereof
CN111549000B (zh) * 2020-06-18 2022-07-29 中国医学科学院整形外科医院 一种过表达Hpgds的重组脂肪干细胞、制备方法及其应用
CN115667259B (zh) 2020-06-19 2025-06-17 佐藤制药株式会社 抑制h-pgds的稠环化合物
CN114085167A (zh) * 2021-12-13 2022-02-25 华中药业股份有限公司 一种杂质ts-3a的制备方法
WO2023111996A1 (en) 2021-12-17 2023-06-22 Reglagene Holding, Inc. Compositions and methods of making and using small molecules in the treatment of cancer
WO2023113023A1 (ja) 2021-12-17 2023-06-22 佐藤製薬株式会社 H-pgdsを阻害するアザインドール誘導体
US20250250265A1 (en) * 2022-04-15 2025-08-07 Vanderbilt University Benzothiazole-phenylsulfonyl-piperidine analogs as activators of nacylphosphatidylethanolamine hydrolyzing phospholipase d
US12215102B2 (en) 2023-02-28 2025-02-04 Reglagene, Inc. Compositions and methods for making and using small molecules for tubulin-targeted therapy in the treatment of cancers and related conditions

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4031221A (en) 1974-06-17 1977-06-21 American Hoechst Corporation Method of treating pain and hypertension
US4956359A (en) 1985-02-28 1990-09-11 A. H. Robins Company, Inc. 3-aryloxy and 3-arylthioazetidinecarboxamides as anticonvulsants and antiepileptics
IE58943B1 (en) 1985-02-28 1993-12-01 Robins Co Inc A H 3-Aryloxy-azetidine-carboxamides
US6809088B2 (en) * 1997-03-24 2004-10-26 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them
GB9801501D0 (en) 1998-01-23 1998-03-18 Cerebrus Ltd Chemical compounds - II
GB9917385D0 (en) 1999-07-23 1999-09-22 Cerebrus Ltd Chemical compounds-I
US6576265B1 (en) 1999-12-22 2003-06-10 Acell, Inc. Tissue regenerative composition, method of making, and method of use thereof
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
AU2005212438A1 (en) * 2004-02-11 2005-08-25 Amgen Inc. Vanilloid receptor ligands and their use in treatments
WO2005094805A1 (ja) 2004-04-01 2005-10-13 Institute Of Medicinal Molecular Design. Inc. イミン誘導体及びアミド誘導体
CA2563963A1 (en) * 2004-04-28 2005-11-10 Pfizer Inc. 3-heterocyclyl-4-phenyl-triazole derivatives as inhibitors of the vasopressin v1a receptor
AP2007004047A0 (en) 2005-01-20 2007-06-30 Pfizer Ltd Substituted triazole derivatives as oxtocin antagonists
US20090221644A1 (en) 2005-06-30 2009-09-03 Stuart Edward Bradley Gpcr Agonists
GB0514017D0 (en) * 2005-07-07 2005-08-17 Ionix Pharmaceuticals Ltd Chemical compounds
TW200720255A (en) 2005-07-13 2007-06-01 Taiho Pharmaceutical Co Ltd Benzoimidazole compound capable of inhibiting prostaglandin d synthetase
JP2007051121A (ja) 2005-07-22 2007-03-01 Taiho Yakuhin Kogyo Kk プロスタグランジンd合成酵素を阻害するピリミジン化合物
DOP2006000210A (es) * 2005-10-04 2007-06-15 Aventis Pharma Inc Compuestos de pirimidina amida como inhibidores de pgds
US20070208426A1 (en) * 2006-03-03 2007-09-06 Sdgi Holdings, Inc. Spinal implant with improved surface properties for delivery
US20090111791A1 (en) * 2006-03-10 2009-04-30 Boehringer Ingelheim International Gmbh Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same
US20110172230A1 (en) 2006-08-23 2011-07-14 Takahiro Ishii Urea compound or salt thereof
CA2672373C (en) * 2006-12-19 2011-08-30 Pfizer Products Inc. Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
NZ579892A (en) 2007-03-30 2012-03-30 Sanofi Aventis Pyrimidine hydrazide compounds as prostaglandin D synthase inhibitors
GB0706793D0 (en) 2007-04-05 2007-05-16 Evotec Ag Compounds
EA017842B1 (ru) * 2008-03-04 2013-03-29 Вернэлис (Р&Д) Лтд. Производные азетидина и их применение
TW201010997A (en) 2008-06-18 2010-03-16 Pfizer Ltd Nicotinamide derivatives
CA2725481A1 (en) 2008-06-18 2009-12-23 Pfizer Limited Nicotinamide derivatives
WO2010024903A1 (en) * 2008-08-29 2010-03-04 Yangbo Feng BENZO[d]OXAZOLES AND BENZO[d]THIAZOLES AS KINASE INHIBITORS
US8536185B2 (en) 2008-09-22 2013-09-17 Cayman Chemical Company, Incorporated Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases
ES2564454T3 (es) 2009-03-09 2016-03-22 Taiho Pharmaceutical Co., Ltd. Compuesto de piperazina que puede inhibir la prostaglandina D sintasa
JPWO2011043359A1 (ja) 2009-10-06 2013-03-04 協和発酵キリン株式会社 芳香族複素環化合物を含有する医薬
NZ599099A (en) 2009-10-08 2013-05-31 Sanofi Sa Phenyloxadiazole derivatives as pgds inhibitors
WO2011090062A1 (ja) 2010-01-22 2011-07-28 大鵬薬品工業株式会社 Pgds阻害作用を有するピペラジン化合物
JP2013526546A (ja) * 2010-05-13 2013-06-24 アムジエン・インコーポレーテツド Pde10阻害剤としてのヘテロアリ−ルオキシヘテロシクリル化合物
AU2011253058A1 (en) * 2010-05-13 2012-12-06 Amgen Inc. Heteroaryloxycarbocyclyl compounds as PDE10 inhibitors
US9050334B2 (en) * 2010-07-16 2015-06-09 Innov88 Llc MIF inhibitors and their uses
PT2616465E (pt) * 2010-09-13 2016-03-09 Novartis Ag Triazino-oxadiazoles
KR101400192B1 (ko) 2010-12-31 2014-05-27 제일모직 주식회사 포지티브형 감광성 수지 조성물, 이를 사용하여 제조된 감광성 수지막 및 상기 감광성 수지막을 포함하는 반도체 소자
WO2012142498A2 (en) * 2011-04-13 2012-10-18 Innovimmune Biotherapeutics, Inc. Mif inhibitors and their uses
SG194625A1 (en) 2011-05-23 2013-12-30 Sanofi Sa Process for the preparation of deuterated compounds containing n-alkyl groups
WO2013074387A1 (en) * 2011-11-14 2013-05-23 Merck Sharp & Dohme Corp. Imidazole derivatives
WO2013146754A1 (ja) * 2012-03-27 2013-10-03 塩野義製薬株式会社 Trpv4阻害活性を有する芳香族複素5員環誘導体
TWI585088B (zh) * 2012-06-04 2017-06-01 第一三共股份有限公司 作爲激酶抑制劑之咪唑并[1,2-b]嗒衍生物
CN105263910A (zh) 2013-02-18 2016-01-20 斯克利普斯研究所 具有治疗潜力的血管加压素受体调节剂
WO2014179144A1 (en) 2013-04-29 2014-11-06 E. I. Du Pont De Nemours And Company Fungicidal heterocyclic compounds
CA2949511A1 (en) 2014-05-19 2015-11-26 Merial, Inc. Anthelmintic compounds
TWI695831B (zh) * 2014-09-13 2020-06-11 香港商南北兄弟藥業投資有限公司 Crth2拮抗劑化合物及其用途
CA2976741C (en) * 2015-03-30 2023-01-17 Mission Therapeutics Limited 1-cyano-pyrrolidine compounds as usp30 inhibitors
CN108430992A (zh) 2015-12-17 2018-08-21 阿斯特克斯医疗公司 作为h-pgds抑制剂的喹啉-3-甲酰胺
JOP20190072A1 (ar) 2016-10-13 2019-04-07 Glaxosmithkline Ip Dev Ltd مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم

Similar Documents

Publication Publication Date Title
JP2019536757A5 (https=)
RU2018126105A (ru) Хинолин-3-карбоксамиды в качестве ингибиторов h-pgds
RU2451674C2 (ru) Пиридинкарбоксамиды в качестве ингибиторов 11-бета-hsd1
US10934261B2 (en) Calpain modulators and therapeutic uses thereof
US7704997B1 (en) Amino-tetrazole analogues and methods of use
JP6938628B2 (ja) 造血器型プロスタグランジンdシンターゼ阻害剤としての1,3二置換シクロブタンまたはアゼチジン誘導体
RU2417994C2 (ru) Производные пиразина, полезные в качестве антагонистов аденозинового рецептора
JP2019502691A5 (https=)
JP2009542638A5 (https=)
RU2491285C2 (ru) Органические соединения
JP2009513575A5 (https=)
JP2010508338A5 (https=)
JP2019077725A5 (https=)
JP2011520896A5 (https=)
RU2016102137A (ru) Первичные карбоксамиды в качестве ингибиторов bik
JP2011503166A5 (https=)
RU2010123874A (ru) Пиридазиноновые производные в качестве ингибиторов parp
JP2010533158A5 (https=)
JP2018530591A5 (https=)
RU2006134020A (ru) Конденсированные производные пиразола
RU2017121044A (ru) Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы
JP2016523911A5 (https=)
RU2005121667A (ru) 5-замещенные пиразиновые или пиридиновые активаторы глюкокиназы
JP2005526723A5 (https=)
RU2005135330A (ru) Ингибиторы фосфодиэстеразы 4